evipedia.ai
← Back

Panax notoginseng for Health & Longevity

Evidence Review created on 09/24/2026 using AI4L / Opus 5.5

Also known as: Notoginseng, Sanqi, San Qi, Sanchi, Tienchi, Tianqi, Tienchi Ginseng, Three-Seven Root, Pseudoginseng, Chinese Ginseng, Radix Notoginseng, Notoginseng Radix et Rhizoma, Panax pseudoginseng var. notoginseng, Notoginseng Saponins, PNS, Xuesaitong, Xueshuantong

Motivation

Panax notoginseng (sanqi, or tienchi ginseng) is the root of a small plant in the ginseng family, grown mainly in the mountains of Yunnan in southwest China. Unlike the better-known Asian ginseng, it has been valued less as an energy tonic and more as a remedy for circulation and bleeding. Its active compounds appear to calm overactive blood platelets and dampen inflammation in blood vessels and nerve tissue.

The root has a long history in Chinese medicine and is the main ingredient of well-known wound powders. In China, purified extracts are licensed medicines used alongside standard care after stroke and in heart disease, and a large, carefully controlled stroke trial has renewed interest. Outside China, it is sold as a supplement for heart and circulation health.

This review examines what human studies show about Panax notoginseng for adults seeking to protect heart and brain health over the long term, how its bleeding-related risks and drug interactions weigh against those findings, and how it is typically dosed, sourced, and monitored.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles that discuss Panax notoginseng in depth, from pharmacology and aging biology to drug interactions.

Only four items are listed: the remaining candidates were systematic reviews (listed below), single clinical trials, or narrow laboratory papers that do not give a high-level overview.

No content on Panax notoginseng was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io; web and site searches returned no article, episode, or protocol on the root. Life Extension mentions it only briefly: short entries in a roundup of adaptogens (herbs said to raise stress resilience) and a ginseng-types article, and one paragraph on intravenous use in its broad blood-clot protocol. None discusses the root in enough depth to serve as an overview.

Grokipedia

Panax notoginseng

An encyclopedic overview of taxonomy, cultivation, traditional uses, phytochemistry, pharmacology, and safety; useful background, though AI-generated and no substitute for primary clinical sources.

Examine

Panax notoginseng

Examine’s supplement page notes that most human studies used standardized Chinese preparations, often combined with other herbs, and treats the cardiovascular evidence as promising but preliminary.

ConsumerLab

No ConsumerLab article on Panax notoginseng exists; the site’s search returned only a hair-loss answer and a manufacturer warning-letter notice that mention the term in passing.

Systematic Reviews

This section lists systematic reviews and meta-analyses (studies that pool the results of many trials) on Panax notoginseng, covering its main benefits and its principal bleeding-related risk.

Mechanism of Action

The root contains over 200 compounds; its effects are attributed mainly to saponins (soap-like plant compounds), chiefly notoginsenoside R1 and ginsenosides Rg1, Rb1, Rd, and Re, together called Panax notoginseng saponins (PNS), plus the amino acid dencichine and polysaccharides (Liu et al., 2020).

  • Antiplatelet and circulatory action: PNS reduce platelet clumping by lowering thromboxane (a platelet activator made via COX, cyclooxygenase, the enzyme aspirin blocks), and relax vessels through nitric oxide.
  • Anti-inflammatory and antioxidant signaling: Saponins suppress NF-κB (a master switch for inflammatory genes) and activate Nrf2 (a switch for the cell’s own antioxidant defenses), protecting brain and heart cells from oxygen deprivation in animals.
  • Competing clot-promoting action: Dencichine speeds clotting through AMPA receptors (glutamate-sensing channels) on platelets (Huang et al., 2014); steaming lowers dencichine, so raw and steamed root act differently.
  • Pharmacology: Oral bioavailability (share of a dose reaching the blood) of the saponins is poor; gut-bacterial β-glucosidases (sugar-cleaving enzymes) strip their sugar groups, yielding smaller, more absorbable metabolites (Wen et al., 2025). After intravenous dosing, R1 and Rg1 clear within hours, whereas Rb1 persists (terminal half-life 32–57 hours; 97–99% protein-bound, so it stays largely in plasma). Selectivity is low (many targets). Rb1 inhibits OATP1B3 (a liver uptake transporter for statins (cholesterol-lowering drugs) and others), while repeated dosing did not induce CYP3A4 (the liver enzyme that clears about half of prescription drugs) (Pintusophon et al., 2019).

A competing view holds that many mechanisms appear only at concentrations unlikely after oral intake.

Historical Context & Evolution

Sanqi (“three-seven”) has been cultivated for centuries in Wenshan, Yunnan. Li Shizhen’s Compendium of Materia Medica (Bencao Gangmu), completed in 1578, recorded it as a prized remedy for wounds, bleeding, bruising, and pain. Its original purpose was paradoxical: stopping bleeding while also “dispersing blood stasis”. In 1902 it became the main disclosed herb in Yunnan Baiyao, a proprietary wound powder.

In the late twentieth century, Chinese manufacturers purified the saponin fraction into licensed medicines, such as Xuesaitong and Xueshuantong capsules and injections, for stroke and heart disease. Hundreds of small Chinese trials followed. A Cochrane review found apparent benefit in stroke but judged seven of eight trials poor quality (Chen et al., 2008). A multicenter, placebo-controlled trial in nearly 3,000 stroke patients later found better functional recovery (Wu et al., 2023).

Interest for health optimization grew from three threads: the root’s circulatory reputation, endurance studies in young adults, and laboratory work by Yunnan Baiyao-affiliated researchers showing longer lifespan in yeast, worms, and mice (Guo et al., 2026). Opinion has not moved in one direction. A manufacturer-sponsored, placebo-controlled trial by Farlong Pharmaceutical in adults with raised cholesterol and blood pressure found no change in either (NCT04069715), so the cardiovascular case for people without disease remains open rather than settled.

Expected Benefits

High 🟩 🟩 🟩

Better functional recovery after stroke

In a 67-center, double-blind (neither patients nor doctors knew assignments) trial of 2,966 adults with ischemic stroke, oral PNS (Xuesaitong soft capsules, 120 mg twice daily for 3 months) raised the share living independently on the modified Rankin Scale (mRS, a 0–6 disability score) (Wu et al., 2023). Meta-analyses of mostly open-label (unblinded) trials agree (Shi et al., 2023), and injected PNS aided recovery after brain hemorrhage (Xu et al., 2014). For healthy adults, this is a contingency benefit rather than prevention.

Magnitude: Functional independence at 3 months was 89.3% versus 82.4% on placebo (odds ratio, OR, the ratio of the odds of an outcome between groups, 1.95; 95% confidence interval, CI, the range likely to contain the true effect, 1.56–2.44).

Fewer angina attacks and cardiac events in coronary disease

In unstable angina, 17 randomized trials of oral PNS reported fewer and shorter chest-pain episodes and less nitroglycerin use (Duan et al., 2018), and 18 trials, mostly of injections, found fewer cardiovascular events (Song et al., 2017). After heart attack, 20 add-on injection trials reported fewer serious cardiac complications (Chen et al., 2024). The effect is attributed to antiplatelet and vessel-relaxing actions. Trials were small, often unblinded, and all Chinese, so the true size is uncertain, and none tested prevention in healthy people.

Magnitude: Angina frequency and duration fell by a mean difference (MD, the average gap between groups) of 1.88 (95% CI 1.72–2.03); cardiovascular events relative risk (RR, risk in the treated group divided by risk in controls) 0.35 (95% CI 0.13–0.94); major adverse cardiac events after heart attack OR 0.32.

Less urinary protein in diabetic kidney disease

Across 24 randomized add-on trials (1,918 patients), notoginseng preparations given with conventional care lowered albuminuria (albumin leaking into urine, an early sign of kidney damage), 24-hour proteinuria (total urinary protein), and serum creatinine (Tang et al., 2020). Albuminuria predicts kidney decline, but no trial measured kidney failure or dialysis. The finding applies chiefly to people with diabetes and early kidney involvement.

Magnitude: Albuminuria MD −26.89 mg (95% CI −33.35 to −20.42); proteinuria −0.32 g per 24 hours; serum creatinine −4.52 μmol/L versus conventional care alone.

Fewer leg-vein clots after orthopedic surgery ⭕️ Not Central to Health & Longevity

Deep-vein thrombosis (DVT, a leg-vein clot that can travel to the lungs) was less frequent across 20 unblinded randomized trials (2,336 patients) given Xueshuantong injection after fracture surgery, with lower D-dimer (a clot-breakdown marker) (Yan et al., 2020). A review of 12 treatment trials found better vein clearance but more adverse events (Li et al., 2021). It bears on in-hospital clot prevention after surgery, not long-term health, and the evidence is injection-only.

Magnitude: DVT incidence was lower than in controls (mostly low-molecular-weight heparin (an injectable anticoagulant) or no clot prevention) after fracture surgery with intravenous use; the review’s text reports the direction and significance but no pooled outcome figure.

Medium 🟩 🟩

Greater endurance exercise capacity

In a 30-day randomized trial, 29 untrained adults taking 1,350 mg/day of notoginseng extended cycling time to exhaustion versus starch placebo, with lower exercise blood pressure and oxygen use (Liang et al., 2005). A pooled analysis of five Panax-genus trials, funded by extract maker Maruzen Pharmaceuticals, supports endurance gains attributed to ginsenoside Rg1 (Ikeuchi et al., 2022). A trial in trained men found no effect on post-exercise muscle soreness (Pumpa et al., 2013).

Magnitude: Endurance time rose by more than 7 minutes and maximal mean arterial pressure (average pressure across each heartbeat) fell from 113 to 109 mm Hg; pooled standardized mean difference (SMD, effect size in standard-deviation units) 0.58 (95% CI 0.22–0.95) across Panax species.

Low 🟩

Lower blood lipids and blood pressure ⚠️ Conflicted

Chinese add-on trials in diabetic kidney disease reported lower LDL-C (“bad” low-density lipoprotein cholesterol) and triglycerides (Tang et al., 2020). A placebo-controlled 12-week sponsor trial in adults with raised LDL-C and blood pressure found no change (NCT04069715). Net reading: no reliable lipid or blood-pressure benefit in adults without disease.

Magnitude: LDL-C −0.94 mmol/L in diabetic kidney add-on trials, versus no difference from placebo at 12 weeks in the sponsor trial (mean change −0.07 versus −0.12).

Lower post-meal blood glucose

In 52 non-diabetic men, 3 g/day of notoginseng for three days lowered blood glucose 30 minutes after a glucose drink and over 90 minutes versus placebo (Liang et al., 2012). This is one short trial measuring an acute marker.

Magnitude: Glucose at 30 minutes was 26.3 mg/dL lower and the 90-minute glucose area 96.5 units lower than placebo.

Local bleeding control ⭕️ Not Central to Health & Longevity

Stopping bleeding is the root’s oldest use. Human evidence comes from Yunnan Baiyao, a proprietary formula led by notoginseng, where 55 mostly low-quality trials suggest better bleeding control (Yang et al., 2014). It bears on acute injury and surgery, not long-term health.

Magnitude: Bleeding-control response RR 1.16 (95% CI 1.06–1.28) for Yunnan Baiyao alone versus control.

Bone preservation

A 2025 review identified eight small clinical trials of notoginseng preparations, mostly patent medicines for osteoporotic fractures, reporting favorable effects (Zhu et al., 2025). Rodent studies show saponins support bone-building cells and curb bone breakdown. The trials were small and of uncertain quality.

Magnitude: Direction favored notoginseng preparations in osteoporosis and osteoporotic-fracture patients; the review reports no pooled outcome figure.

Speculative 🟨

Slower biological aging and longer lifespan

Whole-plant tablets extended lifespan in yeast, worms, and chemotherapy-aged mice and reduced inflammaging (chronic low-grade inflammation of aging) (Guo et al., 2026). Authors are Yunnan Baiyao-linked. Basis: animal and cell data only.

Protection against cognitive decline

Saponins improved memory and brain antioxidant status in senescence-accelerated SAMP8 mice by boosting mitophagy (recycling of damaged mitochondria) (Yang et al., 2024). No human cognitive trials exist; the basis is animal data.

Anticancer activity

Notoginseng ginsenosides killed or slowed several cancer cell lines; gut-bacteria metabolites may be the active forms (Tan et al., 2021; Wang et al., 2016). No human cancer trials exist; the basis is laboratory data.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been shown to change notoginseng’s benefits. Differences in gut bacteria, which convert saponins into absorbable forms, likely matter more and may explain variable responses between individuals.
  • Baseline biomarkers: Benefits appeared in people with existing disease: raised urinary albumin, unstable angina, or recent stroke. In adults with only mildly raised LDL-C and blood pressure, the placebo-controlled trial found no change (NCT04069715), so normal baselines predict little measurable gain.
  • Sex: The largest stroke trial was two-thirds male, and its prespecified sex subgroups showed a consistent benefit (Wu et al., 2023). Ginsenoside Rg1 acts like estrogen in cell studies (Chan et al., 2002), a theoretical but untested reason responses could differ in women.
  • Pre-existing conditions: Stroke, coronary disease, and diabetic kidney disease are the settings with benefit data. People without vascular disease can draw only on small endurance and glucose trials.
  • Age: Stroke and angina trials enrolled mainly adults in their fifties to seventies (median age 62 in the largest trial; Wu et al., 2023), so evidence fits older adults best; endurance and glucose data come from adults aged 20–45.
  • Preparation: Standardized extracts used in trials differ from raw or steamed root powders; steaming converts saponins into other forms and lowers dencichine, so results from one form may not transfer to another.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no randomized trial has shown more adverse events with oral notoginseng than with placebo, and the documented reactions come from observational surveillance of injectable products.

Medium 🟥 🟥

Allergic and skin reactions

Adverse reactions, mostly skin rash and itching, occurred in hospital patients given notoginseng-saponin injections in two surveillance studies of over 60,000 people, co-authored by the manufacturers Kunming Pharmaceutical and Guangxi Wuzhou Pharmaceutical (He et al., 2020; Li et al., 2018). Many appeared within 24 hours and resolved after stopping. Anaphylactoid (allergy-like, not antibody-driven) reactions are linked to large molecules in injectable preparations; oral products list rash as occasional.

Magnitude: Adverse-reaction incidence was 0.33% with Xuesaitong injection (30,008 patients, none severe) and 0.414% with Xueshuantong injection (30,884 patients, 86.7% moderate).

Low 🟥

Added bleeding tendency with anticoagulant and antiplatelet drugs ⚠️ Conflicted

With aspirin, notoginseng deepened platelet inhibition and raised INR (international normalized ratio, a clotting-time measure) across 20 trials, without more bleeding events (Dai et al., 2022). After clot-dissolving stroke treatment, brain bleeding did not rise (Liu et al., 2024). Net reading: laboratory signals are clear; clinical bleeding excess is unproven.

Magnitude: Platelet aggregation rate fell a further 6.10 points and INR rose 0.22 versus aspirin alone; hemorrhagic transformation (bleeding into stroke-damaged brain) RR 0.99 (95% CI 0.36–2.70).

Headache, dizziness, and digestive upset

A drug monograph lists headache, nausea, upset stomach, dizziness, and rash as the most common complaints with oral products. Trials describe such events as mild and no more frequent than control (Wu et al., 2023).

Magnitude: Adverse events of any kind occurred in 2.8% versus 3.6% on placebo over 3 months (serious: 1.0% versus 1.1%); the trial report gives no separate rates for headache, dizziness, or digestive upset.

Liver injury from look-alike “sanqi” herbs

Tu-San-Qi (Gynura japonica), a different plant sold under a similar name, is sometimes mistaken for notoginseng and contains liver-toxic pyrrolizidine alkaloids (Zhu et al., 2021). It causes hepatic sinusoidal obstruction syndrome (blockage of the liver’s small veins). The harm stems from misidentification, not from genuine notoginseng.

Magnitude: About 2,200 cases of Tu-San-Qi-induced hepatic sinusoidal obstruction syndrome were documented in China between 1980 and 2019.

Speculative 🟨

Contaminated raw material

Of 50 Yunnan root samples, 60% exceeded limits for the fungicide quintozene, 56% for cadmium, and 16% for arsenic (Geng et al., 2019). No human harm is documented; the basis is residue testing.

Estrogen-like stimulation

Ginsenoside Rg1 stimulated growth of estrogen-receptor-positive breast cancer cells at tiny concentrations (Chan et al., 2002). Relevance to oral use is unknown; the basis is cell data only.

Nerve toxicity from dencichine

Dencichine is chemically identical to the grass-pea toxin that causes neurolathyrism (a spastic leg paralysis) and acts on AMPA receptors (Huang et al., 2014). No human cases from notoginseng exist; the concern is mechanistic.

Liver and kidney strain with long-term use

Toxicity studies summarized in a 2025 review report good tolerance but suggest long-term use may strain the liver and kidneys (Zhu et al., 2025). No human cases are documented; the basis is toxicology data.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant alters notoginseng’s own risk. In warfarin users, CYP2C9 (the liver enzyme that clears warfarin) and VKORC1 (warfarin’s target enzyme) sensitivity variants already raise bleeding risk, magnifying any added effect.
  • Baseline biomarkers: A low platelet count, prolonged INR, or anemia raises the stakes of any added antiplatelet effect; normal clotting tests make small shifts less consequential.
  • Sex: No sex-specific risk data exist. Women with hormone-sensitive conditions face a theoretical concern from Rg1’s estrogen-like activity, and heavy menstrual bleeding could plausibly worsen with antiplatelet saponins.
  • Pre-existing conditions: Bleeding disorders, peptic ulcer, liver disease affecting clotting, and upcoming surgery raise bleeding risk. Hypertension predicted injection reactions in surveillance data (He et al., 2020).
  • Age: Older adults more often take aspirin, anticoagulants, and multiple drugs, raising interaction and bleeding risk; the largest trial excluded people over 75 (Wu et al., 2023), leaving the oldest adults understudied.

Key Interactions & Contraindications

  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): Caution. In rats, saponins raised warfarin exposure up to 34% and INR up to 28% (Qian et al., 2022), while a drug monograph notes possibly reduced warfarin effect. Consequence: bleeding or clotting. Mitigation: INR check within one week.
  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor, prasugrel): Monitor. Additive platelet inhibition (Dai et al., 2022); in rats, Xuesaitong raised active clopidogrel by suppressing CES1 (a liver enzyme that inactivates clopidogrel) (Ma et al., 2018). Consequence: bruising or bleeding. Mitigation: bleeding-sign surveillance.
  • Clot-dissolving drugs (alteplase, tenecteplase): Caution. Hospital add-on use did not increase brain bleeding (Liu et al., 2024), but effects combine. Consequence: possible hemorrhage. Mitigation: disclosure of supplement use to emergency teams.
  • OATP1B3 substrates (atorvastatin, rosuvastatin, telmisartan, docetaxel): Monitor. Ginsenoside Rb1 is predicted to raise their blood levels (Pintusophon et al., 2019). Consequence: statin muscle pain or drug toxicity. Mitigation: a creatine kinase (muscle-damage marker) test if muscle aches appear.
  • CYP3A4 and CYP1A2 substrates (tacrolimus, cyclosporine, theophylline, clozapine): Monitor. Rats showed CYP3A4 suppression and dose-dependent CYP1A2 (clears caffeine, theophylline) shifts (Qian et al., 2022); human dosing showed no CYP3A induction (Pintusophon et al., 2019). Consequence: altered drug levels. Mitigation: blood-level checks of narrow-margin drugs.
  • Glucose-lowering drugs (insulin, metformin, sulfonylureas such as glipizide): Monitor. Sulfonylureas (drugs that push the pancreas to release insulin) and insulin may combine with notoginseng’s glucose-lowering effect (Liang et al., 2012). Consequence: low blood sugar. Mitigation: glucose checks during the first two weeks.
  • Blood-pressure medications (amlodipine, lisinopril, losartan): Monitor. Notoginseng lowered exercise blood pressure in one trial (Liang et al., 2005). Consequence: minor additive lowering, dizziness. Mitigation: home blood-pressure readings after starting.
  • Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin): Caution. NSAIDs (non-steroidal anti-inflammatory drugs, common pain relievers) impair platelets and irritate the stomach. Consequence: higher gastrointestinal bleeding risk. Acetaminophen avoids the platelet effect for occasional pain.
  • Antiplatelet supplements (fish oil, ginkgo, garlic, high-dose vitamin E, nattokinase, curcumin): Monitor. Additive bleeding tendency is plausible though untested. Consequence: bruising, nosebleeds. Mitigation: limited stacking and bleeding-sign surveillance.
  • Other Panax and notoginseng-containing products (Asian ginseng, American ginseng, Compound Danshen dripping pills, Yunnan Baiyao): Caution. Shared ginsenosides add up. Consequence: unintended double dosing and stronger antiplatelet effect. Mitigation: label review and a count of total intake.
  • Surgery and dental procedures: Caution. Antiplatelet action plus ginsenoside Rb1’s long half-life can increase procedural bleeding. Consequence: excess blood loss. Mitigation: a 14-day pause before elective procedures.

Populations who should avoid Panax notoginseng:

  • Pregnant or breastfeeding women (traditional contraindication; no safety data)
  • People with active bleeding or inherited bleeding disorders (hemophilia, von Willebrand disease, an inherited clotting-protein deficiency) or a platelet count below 100 × 10⁹/L
  • People with peptic ulcer or gastrointestinal bleeding within the past 3 months
  • Anyone within 14 days of scheduled surgery or dental extraction
  • Warfarin users whose INR cannot be checked within one week of starting or stopping
  • People with known allergy to notoginseng or other ginseng-family (Araliaceae) plants
  • People with estrogen-receptor-positive breast or endometrial cancer (theoretical concern from Rg1 cell data)
  • Children and adolescents under 18 (no safety data)

Risk Mitigation Strategies

  • Pre-surgery washout: Stopping notoginseng 14 days before elective surgery or dental extraction limits procedural bleeding; ginsenoside Rb1’s 32–57-hour half-life means residual exposure lasts about a week.
  • INR check with anticoagulants: Warfarin users check INR 5–7 days after starting, changing dose, or stopping notoginseng, catching interaction-driven bleeding or loss of anticoagulation early.
  • Bleeding-sign surveillance: Noting nosebleeds, gum bleeding, easy bruising, or dark stools, and stopping if they appear, prevents hidden bleeding from progressing.
  • Tested products only: Choosing products with lot-specific certificates for arsenic, cadmium, lead, and pesticide residues including quintozene limits the contaminant exposure documented in market roots; verified species identity avoids liver-toxic Tu-San-Qi substitution.
  • Oral rather than injectable forms: Oral use avoids the 0.3–0.4% adverse-reaction rate recorded with injections; observing for rash or itching over the first 24–48 hours catches oral reactions early.
  • Low starting dose: Starting at 500–1,000 mg/day of root powder or 120 mg/day of saponin extract for one week identifies headache, dizziness, or digestive upset before full dosing.
  • Limited stacking: Avoiding simultaneous high-dose fish oil (above 3 g/day), ginkgo, garlic extracts, or vitamin E above 400 IU (international units) daily reduces additive bleeding risk.
  • Glucose checks: People on insulin or sulfonylureas checking fingerstick glucose daily for the first two weeks catch low blood sugar before symptoms escalate.

Therapeutic Protocol

  • Standardized extract: Xuesaitong soft capsules (PNS) 120 mg twice daily (240 mg/day) for 3 months was the regimen in the largest placebo-controlled stroke trial (Wu et al., 2023), used by Chinese stroke and cardiology centers.
  • Whole-root powder: The Chinese Pharmacopoeia lists 3–9 g/day in decoctions (boiled-water extracts) or 1–3 g as an oral powder; supplement trials used 1,350 mg/day for endurance and 3 g/day for glucose.
  • Raw versus steamed root: Traditional practice uses raw root for circulation and bleeding and steamed root as a tonic; steaming converts saponins into rarer ginsenosides and lowers dencichine (Zeng et al., 2026).
  • Competing approaches: Chinese integrative medicine adds notoginseng to aspirin, statins, or kidney drugs in diagnosed disease; Western supplement users take it alone for prevention, an approach without outcome trials. Neither approach is established as the default.
  • Who popularized each approach: Kunming Pharmaceutical (Xuesaitong), Guangxi Wuzhou Pharmaceutical (Xueshuantong), and Dongzhimen Hospital of Beijing University of Chinese Medicine shaped clinical protocols; Farlong Pharmaceutical markets standardized extracts in North America.
  • Time of day: No time-of-day data exist. Trials dosed morning and evening, and taking doses with meals may reduce stomach upset.
  • Half-life: Notoginsenoside R1 and ginsenoside Rg1 clear within hours, while Rb1 has a terminal half-life of 32–57 hours after intravenous dosing (Pintusophon et al., 2019), so Rb1 exposure builds over about a week.
  • Single versus split dose: Split dosing (two or three times daily) matches trial practice and the short half-lives of R1 and Rg1; a single daily dose suits Rb1’s long half-life but is untested.
  • Genetic polymorphisms: No pharmacogenetic dosing guidance exists. Warfarin users carrying CYP2C9 or VKORC1 sensitivity variants, and clopidogrel users with CES1 variants, have more reason for low doses and closer monitoring.
  • Sex: No sex-specific dosing data exist; two-thirds of trial participants were men (Wu et al., 2023). Heavy menstrual bleeding could plausibly worsen with the antiplatelet effect, and no dosing data address it.
  • Age: Adults over 75 were excluded from the largest trial (Wu et al., 2023); older adults commonly start at the low end (1 g/day powder or 120 mg/day extract) because antithrombotic (clot-preventing) co-medication is frequent.
  • Baseline biomarkers: Response signals appeared with raised urinary albumin, recent stroke, or angina; with normal lipids, blood pressure, and glucose, measurable change is unlikely, so baseline values set expectations.
  • Pre-existing conditions: People with vascular disease already on aspirin have the most data; for those with bleeding disorders, ulcers, or anticoagulant therapy, bleeding risk dominates and no dosing data exist.

Discontinuation & Cycling

  • Lifelong versus short-term: No lifelong-use data exist; trials ran 30 days to 3 months. Long-term use is traditional in China but unstudied in controlled settings; practitioners generally frame it as open-ended with periodic review.
  • Withdrawal effects: No withdrawal syndrome has been reported. Stopping removes the antiplatelet effect over days; no evidence shows notoginseng can substitute for prescribed antiplatelet drugs in vascular disease.
  • Tapering: No taper protocol has been described; abrupt stopping, for example before surgery, has no reported rebound, and ginsenoside Rb1 takes about a week to clear.
  • Cycling: No evidence shows tolerance, so cycling is not needed to maintain efficacy. Some practitioners use 8–12 weeks on and 2–4 weeks off to reassess need and bleeding tendency.

Sourcing and Quality

  • Species identity: Quality products name Panax notoginseng on the label; Asian or American ginseng and look-alike Panax japonicus roots differ in composition and uses (Yang et al., 2018); the liver-toxic look-alike Tu-San-Qi (Gynura japonica) is a dangerous substitute.
  • Origin and grade: Wenshan, Yunnan, is the traditional benchmark origin. Roots are graded by “heads” per 500 g (for example, 20-head or 40-head); fewer heads means larger, older, higher-priced roots.
  • Saponin standardization: The Chinese Pharmacopoeia requires combined notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rb1 of at least 5.0% in dried root; quality extracts state their total PNS content.
  • Contaminant testing: Informative third-party certificates of analysis cover arsenic, cadmium, lead, and pesticide residues (quintozene and its toxic impurity hexachlorobenzene), given high exceedance rates in market samples (Geng et al., 2019).
  • Adulteration: The U.S. Food and Drug Administration (FDA) has publicly warned about an imported “notoginseng” gout product containing hidden drug ingredients; brands with good manufacturing practice certification and verifiable testing reduce this risk.
  • Reputable brands: Pharmaceutical-grade options include Xuesaitong soft capsules (Kunming Pharmaceutical), Yunnan Baiyao Group sanqi powders, and Farlong NotoGinseng; independent seals are rare, so lot-specific test results are the main available quality signal.
  • Formulation: Standardized saponin extracts deliver a consistent dose; whole-root powder adds dencichine and polysaccharides; steamed powder has a different saponin profile. The form determines which effects dominate.

Practical Considerations

  • Time to effect: Stroke-recovery benefits emerged over 3 months, endurance gains after 30 days, and post-meal glucose changes within 3 days. Healthy users have no validated marker for tracking benefit.
  • Common pitfalls: Confusing notoginseng with Asian ginseng; combining it with aspirin, anticoagulants, or antiplatelet supplements without monitoring; stacking Chinese formulas that already contain it; forgetting to stop before surgery; assuming hospital-trial results apply to healthy adults.
  • Regulatory status: In the United States it is sold as a dietary supplement under the 1994 Dietary Supplement Health and Education Act, without FDA efficacy review. In China, Xuesaitong and Xueshuantong are licensed medicines, including injectables.
  • Cost and accessibility: Root powder and extracts are inexpensive and widely available; pharmaceutical Xuesaitong capsules are harder to obtain outside Asia. Cost is not a barrier.
  • Evidence transfer: Nearly all positive trials were run in China with Chinese-made products, often without blinding, and several involved manufacturers; the one Western placebo-controlled trial in adults with risk factors was null (NCT04069715).

Interaction with Foundational Habits

  • Sleep: None known. No trial has measured sleep outcomes, and sleep disturbance does not appear among the adverse events reported in the cited trials. No timing adjustment around bedtime is indicated by current data.
  • Nutrition: Indirect. Saponins depend on gut bacteria for conversion into absorbable forms, so a fiber-rich diet supporting a diverse microbiome may aid conversion (untested). Taking doses with meals reduces stomach upset; no nutrient depletion is known. High-dose fish oil and garlic supplements add bleeding tendency.
  • Exercise: Potentiating. 1,350 mg/day for 30 days extended cycling endurance and lowered exercise blood pressure in untrained adults (Liang et al., 2005), but did not ease soreness after downhill running in trained men (Pumpa et al., 2013). A single cycling session did not add to its glucose-lowering effect (Liang et al., 2012).
  • Stress management: None known directly. Notoginseng is classed traditionally as a circulation herb rather than an adaptogen, and no human trial has measured cortisol or perceived stress. Anti-inflammatory effects in animals could theoretically buffer stress-related inflammation.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a complete blood count (CBC) with platelets, prothrombin time with INR, liver enzymes, kidney function with urinary albumin, fasting glucose, a lipid panel, and home blood pressure establish reference points, because notoginseng’s main risks involve clotting and its reported benefits involve vascular and metabolic markers. For people on warfarin or antiplatelet drugs, these values provide the pre-start comparison point.

Ongoing monitoring: Warfarin users repeat INR 5–7 days after starting. Everyone repeats the blood count, clotting tests, and liver and kidney panels at 4–6 weeks, then every 6–12 months while use continues. Lipids, glucose markers, and urinary albumin are rechecked at 3 months, the timeframe in which trials reported changes, to judge whether any benefit is measurable.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Platelet count 200–350 × 10⁹/L Low counts amplify bleeding risk Part of the CBC; conventional range 150–450 × 10⁹/L
Prothrombin time / INR INR 0.9–1.1 (no anticoagulant) Detects clotting shifts On warfarin the prescriber sets the target (usually 2.0–3.0); retest 5–7 days after starting
Hemoglobin Men 14–16 g/dL; women 13–15 g/dL Reveals hidden blood loss Conventional lower limits 13.5 g/dL (men) and 12.0 g/dL (women)
ALT and AST Both below 25 U/L Screens liver strain from herbs or contaminants ALT and AST are alanine and aspartate aminotransferase, liver enzymes; conventional upper limit about 40 U/L; avoid hard exercise 48 hours before
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Tracks kidney function eGFR is estimated glomerular filtration rate, the kidneys’ filtering capacity; conventional threshold above 60
Urine albumin-to-creatinine ratio Below 10 mg/g Tracks kidney-protective effect Conventional cutoff below 30 mg/g; first-morning sample preferred
LDL-C Below 100 mg/dL (2.6 mmol/L) Measures any lipid effect Conventional target below 130 mg/dL for low-risk adults; fast 9–12 hours; pair with triglycerides
Fasting glucose and HbA1c Glucose 75–90 mg/dL; HbA1c below 5.4% Tracks glucose effect and low-sugar risk HbA1c is glycated hemoglobin, a 3-month glucose average; conventional cutoffs below 100 mg/dL and 5.7%; morning fasting draw
hsCRP Below 1.0 mg/L Tracks vascular inflammation hsCRP is high-sensitivity C-reactive protein; conventional below 3.0 mg/L; avoid testing during infection
Blood pressure 110–120 / 70–80 mm Hg Tracks vascular effect Conventional below 130/80 mm Hg; average of morning home readings

Qualitative markers:

  • Easy bruising, nosebleeds, gum bleeding, or dark stools (safety signals)
  • Exercise endurance and perceived effort during usual workouts
  • Daily energy and fatigue levels
  • Digestive comfort, headache, or dizziness after doses
  • Skin rash or itching, especially in the first days
  • Frequency of chest-pain episodes, for people with angina
  • Defining success: stable or improved endurance and vascular markers with no bleeding signals or clotting-test drift at 3 months

Emerging Research

  • Inflammation in coronary disease: A multicenter, double-blind, placebo-controlled Phase 4 trial (NCT06425120) is testing 12 weeks of Xuesaitong soft capsules on hsCRP (high-sensitivity C-reactive protein, an inflammation marker) in 240 patients; recruiting, with completion expected at the end of 2026.
  • Platelet function after stenting: A Phase 3 placebo-controlled trial (NCT06845254) plans 400 patients with acute coronary syndrome (heart attack or unstable angina) after stent placement, measuring whole-blood clotting by thromboelastography; it could show whether added benefit comes with bleeding cost.
  • Clot prevention with bleeding risk: A real-world cohort of 21,600 hospitalized patients (NCT06443905) evaluates Xueshuantong injection for preventing venous thromboembolism (clots in veins and lungs) in people at bleeding risk; status unknown, no results posted.
  • Null Western lipid trial: The completed, manufacturer-sponsored 12-week trial (NCT04069715) of 95 adults found no change in LDL-C, blood pressure, or endothelial function (blood-vessel lining health) versus placebo, weakening the preventive case; no peer-reviewed paper has appeared.
  • Aging biology: Whole-plant notoginseng extended lifespan in yeast, worms, and mice by suppressing CD38 (an enzyme that degrades the energy coenzyme NAD⁺) and inflammatory signals (Guo et al., 2026); no human aging-biomarker trial exists yet.
  • Statin interaction risk: Human pharmacokinetic data predicting OATP1B3 interactions from ginsenoside Rb1 (Pintusophon et al., 2019) point toward a formal clinical interaction study that could change safety advice for statin users.
  • Comparison with antiplatelet drugs: A network meta-analysis (a method comparing many treatments indirectly across trials) of 50 trials ranked notoginseng saponins plus aspirin above aspirin alone for post-stroke function (Zhang et al., 2026); head-to-head randomized trials against dual antiplatelet therapy (aspirin plus a second platelet-inhibiting drug) would test this ranking.

Conclusion

Panax notoginseng is a Chinese root with a long history as a bleeding and circulation remedy, whose active compounds also calm blood platelets and dampen inflammation. For health-focused adults, its evidence divides sharply by setting. In people who have already had a stroke, suffer chest pain from narrowed heart arteries, or have diabetic kidney damage, many Chinese studies, including one large and well-controlled stroke trial, point to better recovery, fewer chest-pain episodes, and less protein in the urine. Most of those studies were small, often lacked placebo controls, and were run by traditional-medicine hospitals or with the product makers themselves, and few have been repeated outside China.

For people without disease, the picture is thin. A short study suggested better endurance, another showed a brief dip in blood sugar after meals, and a maker-funded Western study found no change in cholesterol or blood pressure. Claims of slower aging rest on animal and cell work alone.

The main risks are practical rather than dramatic. Oral use has looked well tolerated, with occasional headache, stomach upset, or rash, while allergic reactions are tied mostly to hospital injections. Its effect on platelets matters for anyone on blood thinners or facing surgery, although studies have not shown more actual bleeding. Contamination with heavy metals and farm chemicals in some roots makes product quality a real part of the risk.

Top - Benefits - Risks - Protocol